research use only

E7386 CBP/beta-catenin Inhibitor

Name: E7386
Brand: Selleck Chemicals
SKU: E1348
Rating: 5 (3 reviews)

Cat.No.: E1348

E-7386 is a selective inhibitor which inhibits interaction between CBP/beta-catenin with IC50 value of 0.0484 μM in HEK293 cells.

Chemical Structure

Molecular Weight: 725.86

Jump to

Quality Control

Batch: E134801 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 99.32%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.32

Related Targets	HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK
Other p300/CBP Inhibitors	Inobrodib (CCS-1477) A-485 Curcumin (Diferuloylmethane) SGC-CBP30 Anacardic Acid CPI-637 I-CBP112 Histone Acetyltransferase Inhibitor II TTK21 GNE-049

Chemical Information, Storage & Stability

Molecular Weight	725.86	Formula	C₃₉H₄₈FN₉O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1799824-08-0	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (137.76 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	CBP/beta-catenin 0.0484 μM
References	[1] https://pubmed.ncbi.nlm.nih.gov/33408116/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-08)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03264664	ACTIVE_NOT_RECRUITING	Advanced Neoplasms	Eisai Inc.	2017-07-27	PHASE1
NCT04008797	ACTIVE_NOT_RECRUITING	Endometrial Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Liver Neoplasms; Colorectal Neoplasms	Eisai Inc.	2019-07-11	PHASE1; PHASE2
NCT03833700	ACTIVE_NOT_RECRUITING	Solid Neoplasms; Colorectal Neoplasms; Gastrointestinal Tumors	Eisai Co., Ltd.	2019-03-05	PHASE1
NCT05091346	COMPLETED	Melanoma; Carcinoma, Hepatocellular; Colorectal Neoplasms	Eisai Inc.	2021-10-27	PHASE1; PHASE2
NCT05607537	COMPLETED	Healthy Volunteers	Eisai Limited	2022-10-17	PHASE1
NCT04840927	WITHDRAWN	Healthy Volunteers	Eisai Limited	2021-04-09	PHASE1

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):